' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Genetic engineering of allergens: future therapeutic products.
Ferreira, F; Wallner, M; Breiteneder, H; Hartl, A; Thalhamer, J; Ebner, C;
Int Arch Allergy Immunol. 2002; 128(3): 171-178.


Hartl Arnulf Josef


Genetic engineering of allergens for specific immunotherapy should aim at the production of modified molecules with reduced IgE-binding epitopes (hypoallergens), while preserving structural motifs necessary for T cell recognition (T cell epitopes) and for induction of IgG antibodies reactive with the natural allergen (blocking antibodies). Common approaches for engineering of hypoallergens usually require knowledge of T and B cell epitopes and involve changing specific base pairs (mutated gene), introduction of a new piece of DNA into the existing DNA molecule (chimeric or hybrid gene), and deletions (truncated gene or fragments). DNA family shuffling has the advantage that it does not require a priori knowledge of structural and functional properties for efficient generation of hypoallergens. The combination of the hypoallergen concept with the Th1-inducing genetic immunization approach might be an attractive alternative for protein-based immunotherapy.

Useful keywords (using NLM MeSH Indexing)



Allergens/therapeutic use*

Desensitization, Immunologic*


Hypersensitivity/drug therapy*


Protein Engineering/methods*

Recombinant Proteins/genetics

Recombinant Proteins/immunology

Recombinant Proteins/therapeutic use

Find related publications in this database (Keywords)

genetic engineering
recombinant allergen